Novo Nordisk (NYSE:NVO)  is one of the globe's biggest drug companies. It's a major player in providing diabetes treatments and is often included in dividend portfolios.

However, patent expirations and new drugs from competitors such as Eli Lilly (NYSE:LLY) are pressuring Novo to spend more on its research pipeline. As a result, dividend investors are right to question whether the risk of sliding sales threatens Novo's dividend payout.

In the following slideshow you'll see whether I think Novo's dividend is safe and gain insight into how the company's dividend yield matches up with industry peers Eli Lilly and AstraZeneca (NYSE:AZN)